603392 万泰生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.087-3.3010.8519.96556.353
总资产报酬率 ROA (%)-0.925-2.7720.6997.81240.693
投入资产回报率 ROIC (%)-1.052-3.1860.8219.62653.875

边际利润分析
销售毛利率 (%)63.91249.32166.19684.15489.536
营业利润率 (%)-13.118-25.7964.17925.43150.031
息税前利润/营业总收入 (%)-12.243-27.0620.41923.59849.361
净利润/营业总收入 (%)-12.626-22.7584.85922.61943.480

收益指标分析
经营活动净收益/利润总额(%)93.021104.692-222.609117.12997.395
价值变动净收益/利润总额(%)-31.228-23.813216.8678.8670.826
营业外收支净额/利润总额(%)-0.0582.425-39.058-0.578-0.239

偿债能力分析
流动比率 (X)4.2314.1764.1623.8583.495
速动比率 (X)3.7463.7863.7333.5193.245
资产负债率 (%)13.17414.31915.25918.01722.580
带息债务/全部投入资本 (%)2.1772.4872.5183.2152.628
股东权益/带息债务 (%)4,445.6573,885.4573,828.6242,999.3583,682.842
股东权益/负债合计 (%)649.946589.990547.096448.572336.767
利息保障倍数 (X)-14.10543.295-0.162-13.986-89.610

营运能力分析
应收账款周转天数 (天)268.269361.900403.347226.37099.701
存货周转天数 (天)350.865305.642419.425365.800224.891